OR WAIT null SECS
InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan Inc.
Groningen, The Netherlands-InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan Inc.
Under the agreement, the companies will expand their existing collaboration and jointly continue to develop long-acting ocular drug delivery products for the treatment of ophthalmic diseases.
Utilizing its patented SynBiosys polymeric drug delivery platform, InnoCore will formulate Allergan’s proprietary drugs into pharmaceutical products expected to be capable of sustained release for many months following a single ocular injection.
“We are very excited that we have expanded this important partnership with Allergan, a company that is widely recognized as a leading company in the development of controlled release ophthalmology medicines,” said Jan Hendriks, chief executive officer of InnoCore. “Expanding our partnership with Allergan is a great opportunity for us to further grow InnoCore in line with our ambitions.”
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.